An eight-month-old baby from Israel has become the first human ever to receive an experimental gene therapy designed to ...

The treatment, administered at Schneider Children’s Medical Center of Israel in Petah Tikva, is a major milestone in the ...

Patients in a Phase I/II clinical trial conducted by UMass Chan Medical School of a dual vector gene therapy for GM2 gangliosidosis, which includes Tay-Sachs and Sandhoff diseases, exhibited a ...

Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector contract development and manufacturing organization (CDMO) specializing in advanced therapies, is pleased to announce its engagement ...

A new study describes the use of artificial intelligence (AI) in designing a new generation of capsids, the structures that envelop genetic material of adeno-associated viruses (AAV), to improve gene ...

SonoThera has raised $125 million in a Series B round to advance its nonviral genetic medicine programmes into clinical trials.

A new therapy for genetic hearing loss has just been approved by the Food and Drug Administration (FDA). The treatment, Otarmeni (lunsotogene parvec-cwha), is the first-ever dual adeno-associated ...

U.S. Market Expected to Grow from USD 0.81 Billion to USD 3.31 Billion by 2035; Europe Market Forecast to Reach USD 2.18 Billion as Advanced Therapy Research Expands.Austin, United States, June 09, ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...

An 8-month-old infant with severe genetic epilepsy has become the first patient in the world to receive an experimental gene ...